Sex: F
Vaccine: COVID19
Symptoms: Blood disorder, Migraine, Oesophageal disorder, Thrombosis
Clinical narrative: Blood clots after covid vaccine; Migraine; Blood disorder after covid vaccine; Esophageal disorder after covid vaccine; This spontaneous case was reported by a consumer and describes the occurrence of THROMBOSIS (Blood clots after covid vaccine) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for an unknown indication.    No Medical History information was reported.   On 01-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) UNK, Citrate free. On an unknown date, the patient experienced THROMBOSIS (Blood clots after covid vaccine) (seriousness criterion medically significant), MIGRAINE (Migraine), BLOOD DISORDER (Blood disorder after covid vaccine) and OESOPHAGEAL DISORDER (Esophageal disorder after covid vaccine). The patient was treated with BOTULINUM TOXIN TYPE A (BOTOX) at an unspecified dose and frequency. At the time of the report, THROMBOSIS (Blood clots after covid vaccine), MIGRAINE (Migraine), BLOOD DISORDER (Blood disorder after covid vaccine) and OESOPHAGEAL DISORDER (Esophageal disorder after covid vaccine) had not resolved.            Company comment: This is a spontaneous case concerning an adult female patient on treatment with Adalimumab for an unknown indication, who experienced the serious (medically significant) unexpected event thrombosis, on an unknown date after the second dose of mRNA-1273.  Migraine, esophageal disorder and blood disorder were also reported as non-serious events. It was reported that patient was treated with botox. Clinical course, diagnostic tests and treatment details were not provided. Adalimumab was reported as a co-suspect product. Events seriousness captured as per list. The benefit-risk relationship of mRNA-1273 is not affected by this report.  No concomitant medications were reported. Reporters causality for all events was not reported with respect to Humira drug. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.; Sender's Comments: Company comment: This is a spontaneous case concerning an adult female patient on treatment with Adalimumab for an unknown indication, who experienced the serious (medically significant) unexpected event thrombosis, on an unknown date after the second dose of mRNA-1273.  Migraine, esophageal disorder and blood disorder were also reported as non-serious events. It was reported that patient was treated with botox. Clinical course, diagnostic tests and treatment details were not provided. Adalimumab was reported as a co-suspect product. Events seriousness captured as per list. The benefit-risk relationship of mRNA-1273 is not affected by this report.